Deutsche Märkte geschlossen

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
147,46+0,96 (+0,66%)
Ab 03:55PM EDT. Markt geöffnet.
Melden Sie sich an, um eine Nachricht zu posten.
  • J
    Joe
    $SLS conversation
    Massively undervalued Equity $Jazz paid $1.5B for Cpxx when it released its p3 data. SLS now trades for .0375 or 3.75% of what it will be worth when the AML Approval happens in 12 months no or sooner when the idmc halts the trial for efficacy.
  • J
    Joe
    $SLS conversation
    $Jazz paid $1.5B for Cpxx AML agent, similar to Gps P3 market. Equal to $75/sls share +2,770% ROI FDA approval 12 months If Idmc doesn’t halt this sooner.
  • R
    Real Immuno Investor 10
    $SLS conversation
    Can any of the Short Lowlife Refute this Direct Market Comp? for AML only ?
    SLS has a MKT Cap of $113M vs $1.5B $JAZZ paid for $CPXX when it released its p3 data - GPS p3 data in months - equates to $95 Per SLS share. https://www.wsj.com/articles/jazz-pharmaceuticals-agrees-to-buy-celator-for-about-1-5-billion-1464686352

    Cantor Fitz Analysts proj revenue of $200M in initial Niche cr2 setting.
    SELLAS is a late-stage immune-oncology company that is focused on novel cancer vaccines. The lead drug candidate, galinpepimut-S (GPS), is a peptide vaccine that target Wilms tumor 1 and is in a Phase 3 trial for acute myeloid leukemia (AML).

    Even in the initial niche target population of AML patients after second complete remission, “we project the peak sales to be about $200-million” Li Watsek

    “Overtime, we think GPS has the potential to broaden into AML patients after first complete remission, as well as in other indications with combinations”

    Gps is Priceless for AML patients. What will big pharma pay for $800M in Potential AML Revenue?

    Buy and Hold
    Jazz Pharmaceuticals agreed to buy Celator Pharmaceuticals in a roughly $1.5 billion deal that represents a huge premium for a company with a promising leukemia drug but no revenue.
    Jazz Pharmaceuticals agreed to buy Celator Pharmaceuticals in a roughly $1.5 billion deal that represents a huge premium for a company with a promising leukemia drug but no revenue.
    www.wsj.com
  • 2
    21 months of Os vs 5
    $SLS conversation
    4 News hits before the FDA later this year. 1. Nps Twin Glsi trial, 2 NPs license, 3 Gps+Opdivo Meso trial data, 4 Gps + Keytruda ovarian data unlocked.
    $17, then $70 and $170 in 2022 $MRK Gps Keytruda Phase 2 data is now locked, and will be definitively Binary. There are no effective treatments for platinum Resistant OC patients. Should these results -Mid Year confirm earlier data (100% Survival Rates), Gps is immediately worth $1B just for OC. Also, AML Phase 3 Approval zone 4 months away. $Jazz Paid 1.5B for $cpxx when it reported its P3 data .. Tuck a Few away while they’re on sale and ‘stay tuned.’
    https://www.globenewswire.com/news-release/2021/06/30/2255695/0/en/SELLAS-Reports-Promising-Updated-Clinical-Data-and-Initial-Immune-Response-Profiles-from-Ongoing-Phase-1-2-Study-of-Galinpepimut-S-GPS-Combined-with-Keytruda-for-Treating-WT1-Advan.html
    Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
    Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
    www.globenewswire.com
  • 2
    21 months of Os vs 5
    $SLS conversation
    4 News hits before the FDA later this year. 1. Nps Twin Glsi trial, 2 NPs license, 3 Gps+Opdivo Meso trial data, 4 Gps + Keytruda ovarian data unlocked.
    $17, then $70 and $170 in 2022 $MRK Gps Keytruda Phase 2 data is now locked, and will be definitively Binary. There are no effective treatments for platinum Resistant OC patients. Should these results -Mid Year confirm earlier data (100% Survival Rates), Gps is immediately worth $1B just for OC. Also, AML Phase 3 Approval zone 4 months away. $Jazz Paid 1.5B for $cpxx when it reported its P3 data .. Tuck a Few away while they’re on sale and ‘stay tuned.’
    https://www.globenewswire.com/news-release/2021/06/30/2255695/0/en/SELLAS-Reports-Promising-Updated-Clinical-Data-and-Initial-Immune-Response-Profiles-from-Ongoing-Phase-1-2-Study-of-Galinpepimut-S-GPS-Combined-with-Keytruda-for-Treating-WT1-Advan.html
    Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
    Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
    www.globenewswire.com
  • R
    Real Immuno Investor 10
    $SLS conversation
    After CPXX reported its p3 data, Jazz bought Cpxx for $1.5B their AML drug isn't half the drug GPS is - SLS trades for .08B $Jazz Pharmaceuticals said it will acquire Celator in a deal worth a total of $1.5 billion. The Irish company will gain access to the Ewing, NJ-based company's lead experimental blood cancer drug Vyxeos (CPX-351), which just last week gained an FDA “breakthrough therapy” designation.

    The FDA’s designation--which speeds up its review of a new medicine--is for patients with therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

    A recent Phase III trial met its primary endpoint by showing statistically significant improvement in overall survival; detailed data will be presented at ASCO next week.

    Its current data for the drug showed median overall survival for patients treated with Vyxeos was 9.56 months compared with 5.95 months--a 3.61-month improvement in favor of Celator’s treatment against a chemotherapy agent known as 7+3.
  • 2
    21 months of Os vs 5
    $SLS conversation
    4 Due News hits before the FDA Approval later this year.
    Nps Twin Glsi trial, NPs license, Gps+Opdivo Meso trial data, and Gps + Keytruda ovarian cancer data unlocked.
    $16, then $60 and $160 in 2022 $MRK Gps Keytruda Phase 2 data is now locked, and will be definitively Binary. There are no effective treatments for platinum Resistant OC patients. Should these results -Mid Year confirm earlier data (100% Survival Rates), Gps is immediately worth $1B just for OC. Also, AML Phase 3 Approval zone 4 months away. $Jazz Paid 1.5B for $cpxx when it reported its P3 data .. Tuck a Few away while they’re on sale and ‘stay tuned.’
    https://www.globenewswire.com/news-release/2021/06/30/2255695/0/en/SELLAS-Reports-Promising-Updated-Clinical-Data-and-Initial-Immune-Response-Profiles-from-Ongoing-Phase-1-2-Study-of-Galinpepimut-S-GPS-Combined-with-Keytruda-for-Treating-WT1-Advan.html
  • 2
    21 months of Os vs 5
    $SLS conversation
    4 News hits before the FDA AML Approval later this year.
    1. Nps Twin Glsi trial, 2 NPs license, 3 Gps+Opdivo Meso trial data, 4 Gps + Keytruda ovarian data unlocked.
    $16, then $60 and $160 in 2022 $MRK Gps Keytruda Phase 2 data is now locked, and will be definitively Binary. There are no effective treatments for platinum Resistant OC patients. Should these results -Mid Year confirm earlier data (100% Survival Rates), Gps is immediately worth $1B just for OC. Also, AML Phase 3 Approval zone 4 months away. $Jazz Paid 1.5B for $cpxx when it reported its P3 data .. Tuck a Few away while they’re on sale and ‘stay tuned.’
    https://www.globenewswire.com/news-release/2021/06/30/2255695/0/en/SELLAS-Reports-Promising-Updated-Clinical-Data-and-Initial-Immune-Response-Profiles-from-Ongoing-Phase-1-2-Study-of-Galinpepimut-S-GPS-Combined-with-Keytruda-for-Treating-WT1-Advan.html

    Pardon the reposting, I do it to counter the malicious misinformation being spammed by the shorts.
    Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
    Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
    www.globenewswire.com
  • 2
    21 months of Os vs 5
    $SLS conversation
    4 News hits before Gps FDA AML Approval later this year. 1. Nps Twin Glsi trial, 2 NPs license, 3 Gps+Opdivo Meso trial data, 4 Gps + Keytruda ovarian data unlocked. $16, then $60 and $160 in 2022 $MRK Gps Keytruda Phase 2 data is now locked, and will be definitively Binary. There are no effective treatments for platinum Resistant OC patients. Should these results -Mid Year confirm earlier data (100% Survival Rates), Gps is immediately worth $1B just for OC. Also, AML Phase 3 Approval zone 4 months away. $Jazz Paid 1.5B for $cpxx when it reported its P3 data .. Any single digit gets are stolen and ‘stay tuned.’
  • 2
    21 months of Os vs 5
    $SLS conversation
    4 News hits before Gps FDA AML Approval later this year. 1. Nps Twin Glsi trial, 2 NPs license, 3 Gps+Opdivo Meso trial data, 4 Gps + Keytruda ovarian data unlocked.
    $16, then $60 and $160 in 2022 $MRK Gps Keytruda Phase 2 data is now locked, and will be definitively Binary. There are no effective treatments for platinum Resistant OC patients. Should these results -Mid Year confirm earlier data (100% Survival Rates), Gps is immediately worth $1B just for OC. Also, AML Phase 3 Approval zone 4 months away. $Jazz Paid 1.5B for $cpxx when it reported its P3 data .. Any single digit gets are stolen and ‘stay tuned.’
  • 2
    21 months of Os vs 5
    $SLS conversation
    4 News hits before the FDA AML Approval later this year. 1. Nps Twin Glsi trial, 2 NPs license, 3 Gps+Opdivo Meso trial data, and 4 Gps + Keytruda ovarian cancer data unlocked.
    $16, then $60 and $160 in 2022 $MRK Gps Keytruda Phase 2 data is now locked, and will be definitively Binary. There are no effective treatments for platinum Resistant OC patients. Should these results -Mid Year confirm earlier data (100% Survival Rates), Gps is immediately worth $1B just for OC. Also, AML Phase 3 Approval zone 4 months away. $Jazz Paid 1.5B for $cpxx when it reported its P3 data .. Tuck a Few away while they’re on sale and ‘stay tuned.’
    https://www.globenewswire.com/news-release/2021/06/30/2255695/0/en/SELLAS-Reports-Promising-Updated-Clinical-Data-and-Initial-Immune-Response-Profiles-from-Ongoing-Phase-1-2-Study-of-Galinpepimut-S-GPS-Combined-with-Keytruda-for-Treating-WT1-Advan.html
    Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
    Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
    www.globenewswire.com
  • 2
    21 months of Os vs 5
    $SLS conversation
    Investors talking about 2,000% gains: $6.12 * 2,000% $122.40 per share *15.8M total SLS Share, $1.9B in Market Cap value - a little light for an AML Immunotherapy with proj Rev of $800M. $Jazz did buy Cpxx ($200M in proj rev.) for $1.5B, when it released its P3 Data - its drug treats the same Exact patients as the SLS drug. Jazz Pharma to buy Celator in $1.5 billion deal https://www.yahoo.com/news/jazz-pharma-buy-celator-1-080728521.html
    SELLAS is a late-stage immune-oncology company that is focused on novel cancer vaccines. The lead drug candidate, galinpepimut-S (GPS), is a peptide vaccine that target Wilms tumor 1 and is in a Phase 3 trial for acute myeloid leukemia (AML).

    “We expect to get the interim data of the trial in the first half of 2022 and topline data in 2022. If the results are positive, we think GPS can be a commercial product in 2023,” writes analyst Li Watsek.

    Even in the initial niche target population of AML patients after second complete remission, “we project the peak sales to be about $200-million,” she added.

    “Overtime, we think GPS has the potential to broaden into AML patients after first complete remission, as well as in other indications with combinations,” Ms. Watsek said.
  • 2
    21 months of Os vs 5
    $SLS conversation
    $6 will be $16, then $60 and $160 in 2022 $MRK Gps Keytruda Phase 2 data is now locked, and will be definitively Binary. There are no effective treatments for platinum Resistant OC patients. Should these results Mid Year confirm earlier data (100% Survival Rates), Gps is immediately worth $1B just for OC. Also, AML Phase 3 Approval zone 4 months away. $Jazz Paid 1.5B for $cpxx when it reported + P3 data .. Tuck a Few away while they’re on sale and ‘stay tuned.’
    https://www.globenewswire.com/news-release/2021/06/30/2255695/0/en/SELLAS-Reports-Promising-Updated-Clinical-Data-and-Initial-Immune-Response-Profiles-from-Ongoing-Phase-1-2-Study-of-Galinpepimut-S-GPS-Combined-with-Keytruda-for-Treating-WT1-Advan.html
    Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
    Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
    www.globenewswire.com
  • 2
    21 months of Os vs 5
    $SLS conversation
    $6 will be $16, then $60 and $160 in 2022 $MRK Gps Keytruda Phase 2 data is now locked, and will be definitively Binary. There are no effective treatments for platinum Resistant OC patients. Should these results -Mid Year confirm earlier data (100% Survival Rates), Gps is immediately worth $1B just for OC. Also, AML Phase 3 Approval zone 4 months away. $Jazz Paid 1.5B for $cpxx when it reported its P3 data .. Tuck a Few away while they’re on sale and ‘stay tuned.’
    https://www.globenewswire.com/news-release/2021/06/30/2255695/0/en/SELLAS-Reports-Promising-Updated-Clinical-Data-and-Initial-Immune-Response-Profiles-from-Ongoing-Phase-1-2-Study-of-Galinpepimut-S-GPS-Combined-with-Keytruda-for-Treating-WT1-Advan.html
    Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
    Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
    www.globenewswire.com
  • 2
    21 months of Os vs 5
    $SLS conversation
    4 Due News hits before the FDA Approval later this year. ( posting for the short liars )
    Nps Twin Glsi trial, NPs license, Gps+Opdivo Meso trial data, and Gps + Keytruda ovarian cancer data unlocked.
    $16, then $60 and $160 in 2022 $MRK Gps Keytruda Phase 2 data is now locked, and will be definitively Binary. There are no effective treatments for platinum Resistant OC patients. Should these results -Mid Year confirm earlier data (100% Survival Rates), Gps is immediately worth $1B just for OC. Also, AML Phase 3 Approval zone 4 months away. $Jazz Paid 1.5B for $cpxx when it reported its P3 data .. Tuck a Few away while they’re on sale and ‘stay tuned.’
    https://www.globenewswire.com/news-release/2021/06/30/2255695/0/en/SELLAS-Reports-Promising-Updated-Clinical-Data-and-Initial-Immune-Response-Profiles-from-Ongoing-Phase-1-2-Study-of-Galinpepimut-S-GPS-Combined-with-Keytruda-for-Treating-WT1-Advan.html
    Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
    Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
    www.globenewswire.com
  • k
    kC
    -----Extending Overall Survival from 5 months to 9.56 months of os is worth 1.5 B so what should the Sls drug be worth / In February 2020, SELLAS announced positive follow-up data from its Phase 2 study of GPS in CR2 AML patients. The final data showed a median overall survival (OS) of 21.0 months, at a median follow-up of 30.8 months, in patients receiving GPS compared to 5.4 months in patients treated with best standard care (p-value < 0.02). GPS therapy continued to be well tolerated throughout the study. /-/ Undervalued by 20x /Celator's $CPXX stock popped in March when it announced Vyxeos significantly improved overall survival in secondary AML patients (those w/ a previous malignancy) compared to the standard of care, from - 5.95 months, to 9.56 months - VS
    The final analysis GPs the SLS drug shows a median OS of 21 months in the GPS-treated patient cohort. Celator's stock shot up again at the end of May when $Jazz Pharmaceuticals announced it would buy the company for $1.5 billion, or about $30.25 per share, in cash.
    GPS Results are better 9.5 months of Survival for CPXX vs 21 months with GPs
  • j
    jim
    $SLS conversation
    1 Day First Hit (Reposting for vector-aka-dmanakajason) Expect a quadruple+ from upcoming Catalysts
    1. Pr announcing Annual Meeting is Now officially due
    2. Upside Earnings beat with Positive net income - 3 Days
    3. GLSI like Nps trial Results are imminent truly imminent - Any day now
    4. Gps Phase 3 Enrollment Complete announcement - Any day now
    5. Nps Out License - over due
    6. Gps Euro License - any day now
    7. More Milestone Money - March 12
    a quick list of known valuable catalysts
    Tiny float, No debt, Multi-billion and market comps. In the past couple of years, after valuable trial data was released the price would launch, shorts expected to cover with shares from an offering, so the price tanked -didn’t hold the value of real clinical data. That cycle is over - given the strong cash position $40M or so and microscopic burn rate of $3.5/4M quarter and the $202m licensee already paying.
    The earnings and cash pile announcement will motivate institutions to take a look at the Assets value. They will see $SLS currently trades at a huge discount to actual market comps. $jazz bought $cpxx for $1.5b when it extended survival to 5.95 months vs 21 months for Gps.
    $sls key drug Gps, extended survival to 21 months in the same exact patient setting.
    Yet this only trades for less than 8% of that?
    Gps treats 20 cancers in total.
    $200 per share this year on P3 Fda review
  • j
    jim
    $SLS conversation
    4 Days First HIt Reposting for vec and jay Could easily quadruple from the Upcoming Catalysts
    1. Pr announcing Annual Meeting is Now officially due
    2. Upside Earnings beat with Positive net income - 3 Days
    3. GLSI like Nps trial Results are imminent truly imminent - Any day now
    4. Gps Phase 3 Enrollment Complete announcement - Any day now
    5. Nps Out License - over due
    6. Gps Euro License - any day now
    7. More Milestone Money - March 12
    a quick list of known valuable catalysts
    Tiny float, No debt, Multi-billion and market comps. In the past couple of years, after valuable trial data was released the price would launch, shorts expected to cover with shares from an offering, so the price tanked -didn’t hold the value of real clinical data. That cycle is over - given the strong cash position $40M or so and microscopic burn rate of $3.5/4M quarter and the $202m licensee already paying.
    The earnings and cash pile announcement will motivate institutions to take a look at the Assets value. They will see $SLS currently trades at a huge discount to actual market comps. $jazz bought $cpxx for $1.5b when it extended survival to 5.95 months vs 21 months for Gps.
    $sls key drug Gps, extended survival to 21 months in the same exact patient setting.
    Yet this only trades for less than 8% of that?
    Gps treats 20 cancers in total.
    $200 per share this year on P3 Fda review
  • R
    Real Immuno Investor 10
    $SLS conversation
    Car T vectored Tcell drugs include significant side affects and costs - 400 -600K per patient ... Nps and Gps+ are off the shelf safe effective multivalent T Cell activators with proven durable anti cancer immunogenic ability preventing cancer recurrence For TNBC DCIS breast cancer patients and in Metastatic Active tumor Mesothelioma and Ovarian Cancer. And Increased survival by 400% from 5.95 months to 21 months for AML patients in end stage cancer. The drug that produced 5 months of survival in secondary remission patients was sold to $jazz for $1.5B - lastly packing it in, $SLS just picked up the first milestone payment from a $200m license, will be the reason for an upside Positive earnings surprise in the 10K.
  • j
    jamboree
    $SLS conversation
    $CPXX bought by $JAZZ - Great Efficacy Comp Data / Market size info stats this street(sorry)article B4 the buyout.
    Gps extended Overall to 21 months for these patients: More than 300 elderly patients with secondary (high risk) AML were randomized equally to treatment with Vyxeos or the 7+3 regimen. The primary endpoint of the study was overall survival.

    Celator was proven right. Treatment with Vyxeos reduced the risk of death by 31% compared to 7+3. The survival benefit favoring Vyxeos -- 3.6 months at the median -- was statistically significant, achieving the primary endpoint of the study. ( Sls is 5x better than this $1.5B drug )

    As you can see below give the market size for GPs, $SLS is Undervalued by 10x
    Celator believes it can achieve U.S. and European Vyxeos sales in the range of $200 million to $270 million based on the subset of AML patients enrolled in the phase III study. If use of Vyxeos is expanded into other AML patient populations, peak sales could reach $690 million to $780 million, the company estimates.
    https://www.thestreet.com/investing/stocks/celator-pharma-surprises-with-blood-cancer-drug-survival-benefit-13494703
    Based on the positive study results, Celator expects to seek regulatory approval for Vyxeos in the U.S. and Europe later this year.
    Based on the positive study results, Celator expects to seek regulatory approval for Vyxeos in the U.S. and Europe later this year.
    www.thestreet.com